SALUTARIS-MEDICAL
Today, Salutaris Medical Devices, Inc. (SalutarisMD® ) announced that during its upcoming presentation at the Ophthalmology Futures European Forum on September 8, the Company will introduce its new generation, commercial ready, episcleral brachytherapy applicator system. The presentation by Dr. Laurence Marsteller, CEO, will discuss how the new SalutarisMD system (SMD-DA™) is designed to deliver improved dosimetry to wet AMD lesions and improved ease of use for retinal surgeons. The Company will also display the system at its exhibitor’s booth. ISO audits for certification and CE application are underway and the Company expects to receive ISO 13485 certification and the CE Mark on the commercial product by year end.
The Company recently received US regulatory approval for an upcoming clinical study utilizing the new and improved device. The Company has successfully completed a previous study with a first generation clinical device. While that study was not intended to be extrapolated for statistical significance, individual subject results were tracked. In three of the four treatment-naïve patients and one of the two chronically treated wet AMD patients, best corrected visual acuity (BCVA) improved at two years following SMD-1™ treatment (range: +4 to +25 ETDRS letters). In addition, two treatment-naïve patients did not require any further anti-VEGF injections during the following two years.
As wet AMD is the leading cause of blindness worldwide, there is an urgent and compelling need for new therapies that improve visual outcomes and lower the burden of care. Dr. Laurence Marsteller commented that, “Our new commercial ready applicator system is a significant marker of SalutarisMD’s continued progress and we are looking forward to positively affecting patient outcomes.”
(Caution: Investigational Device, Limited to Investigational Use).
About SalutarisMD
SalutarisMD (Salutaris Medical Devices, Inc. and Salutaris Medical Devices, Ltd.) is a pre-revenue medical device company developing an investigational ophthalmic treatment for wet age-related Macular Degeneration (wet AMD). The SalutarisMD patented technology incorporates a minimally invasive single-use brachytherapy procedure that can be performed in an outpatient setting in approximately 15 minutes. This method delivers localized tissue irradiation that is performed under the direct care and expertise of a retina specialist. For more information visit www.SalutarisMD.com or www.SalutarisMD.co.uk .
About Ophthalmology Futures Forums
Ophthalmology Futures Forums are clinician-driven innovation meetings focusing on technology as well as financing, market access and commercialisation of new ophthalmic products. They cover all aspects of global innovation in ophthalmic devices, diagnostics and pharmaceuticals. For more information visit http://www.ophthalmology-futures.com .
Salutaris Medical Devices, Inc.
4340 N. Campbell Ave. Suite 266
Tucson,
AZ 85718
+1 520-638-7518
www.SalutarisMD.com
Salutaris Medical Devices, Ltd.
Level 1, Bessemer Building Imperial
College
London SW72AZ +44 (0) 203 282 7166
www.SalutarisMD.co.uk
View source version on businesswire.com: http://www.businesswire.com/news/home/20160905005056/en/
Contact:
SalutarisMD
Joanne Vitali, Communications Director
+1
610-518-5405
jvitali@SalutarisMD.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Samsung Epis Holdings Delivers Business Updates at the 44th J.P. Morgan Healthcare Conference15.1.2026 01:40:00 CET | Press release
Samsung Bioepis plans to secure 20 biosimilars in its products and pipeline by 2030The new pipeline will include dupilumab, guselkumab, ixekizumab, fam-trastuzumab deruxtecan-nxki, vedolizumab, and ocrelizumab, in addition to pembrolizumab currently in Phase 1 and 3 clinical studiesHaving secured investigational new drug application (IND) clearance from the U.S. Food and Drug Administration (FDA), SBE303, Samsung Bioepis’ novel antibody-drug conjugate (ADC) engineered to target Nectin-4, will enter into the Phase 1 first-in-human clinical trial this yearSamsung Bioepis plans to add one novel therapeutic candidate in clinical study every year Samsung Epis Holdings (KRX: 0126Z0) today shared corporate progress and updates at the 44th J.P. Morgan Healthcare Conference. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260114206458/en/ Kyung-Ah Kim, President and Chief Executive Officer (CEO) of Samsung Epis Holdings "2026 is a mon
Most Delivered Light-Entry Jet Cessna Citation M2 Gen2 With Garmin Autothrottles Enters Into Service, Bringing Greater Control and Precision to Pilots14.1.2026 20:30:00 CET | Press release
The Cessna Citation M2 Gen2 with Garmin Autothrottles recently entered into service. Certified by the Federal Aviation Administration in October 2025, the integration of Garmin’s Autothrottle system in the Citation M2 Gen2 further supports the most delivered light-entry jet’s capabilities by bringing greater control and precision to pilots. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260114646844/en/ Most delivered light-entry jet Cessna Citation M2 Gen2 with Garmin Autothrottles enters into service, bringing greater control and precision to pilots (Photo Credit: Textron Aviation). The Cessna Citation M2 Gen2 is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company. “We continue to invest in our products to provide customers with the best aviation experience in the world," said Lannie O’Bannion, senior vice president, Sales & Marketing. “The M2 Gen2 leads its segment as the most delivered
TwentyTwo Real Estate and Farallon Capital Complete €761 Million Investment in Isemia, a €1.2bn Healthcare Real Estate Company Created With emeis14.1.2026 18:30:00 CET | Press release
TwentyTwo Real Estate, an independent European real estate investment and management firm, announces the completion, alongside Farallon Capital, of a €761 million investment that led to the creation of Isemia (www.isemiabyemeis.com), a leading healthcare real estate company holding a €1.2 billion portfolio of assets operated by emeis. The transaction represents a significant milestone in TwentyTwo Real Estate’s long-term investment strategy focused on healthcare and operational living real estate. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260114262830/en/ Fachklinik Schömberg Isemia comprises 68 high-quality assets across France, Germany and Spain, with a balanced mix of nursing homes (48%) and clinics (52%). The portfolio benefits from strong fundamentals and resilient operating performance. All properties will continue to be operated by emeis under long-term lease agreements, ensuring continuity of care for residents
AI’s Water Demand to Surge Nearly 130% by 2050 – New Research Shows How to Build a Water-Secure AI Economy14.1.2026 16:00:00 CET | Press release
Analysis finds AI could add 30 trillion liters of annual water demand, but targeted reuse and digital infrastructure investments can substantially offset demand and protect communities The rapid global expansion of artificial intelligence is set to drive a 129% increase in water demand across the AI value chain by 2050, according to new research by Xylem (NYSE: XYL) and Global Water Intelligence (GWI). Watering the New Economy: Managing the Impacts of the AI Revolution provides the most comprehensive assessment to date of how AI is reshaping global water use. It also highlights practical ways to meet that demand while strengthening water security for communities. Spending on AI is forecast to approach $2 trillion in 2026,1 accelerating infrastructure build-out worldwide. By the middle of the century, this expansion is projected to add 30 trillion liters of water demand, annually, fueled by a surge in power generation (~54% of the increase), semiconductor fabrication (~42%), and data ce
ACCELQ Crowned Leader and Customer Favorite in The Forrester Wave™ for Autonomous Testing Platforms14.1.2026 16:00:00 CET | Press release
Agentic Test Automation Pioneer Caps Record-Breaking Year of Growth and "AI-Based Engineering Solution of the Year" Honors Forrester has named ACCELQ a Leader in The Forrester Wave™: Autonomous Testing Platforms, Q4 2025. This marks the third consecutive Wave in which ACCELQ has been recognized as a Leader. Notably, this evaluation placed strong emphasis on generative AI innovation and real-world customer adoption. ACCELQ received the highest scores for both capabilities and vision and was the only platform to be recognized as a Customer Favorite, earning a "double halo" for exceptional customer endorsement. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260113112861/en/ ACCELQ recognized as a Leader and Customer Favorite in The Forrester Wave™️: Autonomous Testing Platforms, Q4 2025, validating its agentic, GenAI-embedded testing vision. According to the Forrester report, ACCELQ received the highest score among all evaluate
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom